ILC Dover LP, specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, has opened a new facility in Lillington, North Carolina to offer pre-filled trusted-weight cGMP raw materials for the growing biomanufacturing market.
Biomerics, the leading vertically integrated medical device contract manufacturer in the interventional device market, announced completion of a 26,000 sq. ft. expansion of its Monroe, CT facility. The Monroe facility is the headquarters of Biomerics’ micro-metals processing business and specializes in the design, development, and manufacture of complex micromachined and laser-processed components for the interventional robotic medical device market.
Life Science Outsourcing, Inc., a leading contract manufacturer and value-added service provider to medical device and life science companies, announced today that it has acquired J-Pac Medical, a manufacturing, packaging and sterilization outsourcing partner to medical device and diagnostic companies.
SK pharmteco, is pleased to announce $35m investment for the initial phase of an expansion plan for SK biotek Ireland’s Dublin-based pharmaceutical manufacturing plant.
Pfizer Inc. has planned a $120 million investment at its Kalamazoo manufacturing facility to support the production of its COVID-19 antiviral treatment, Paxlovid.
Engineered to meet unique automation needs across various industries, Epson Robots, the #1 SCARA robot manufacturer in the world, today announced the new GX Series robot lineup with the GX4 and GX8.
The new Biomerics office will be equipped with multiple balloon-forming machines, state-of-the-art test equipment, and a cleanroom that is ISO 13485:2016 certified.
Through this investment, the Sligo site will feature Class 7 cleanroom manufacturing environments and state-of-the art thermoforming operations, fully certified to ISO 13485 standards and meeting the highest regulatory requirements.
Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has announced completion of additions to its research capacity and services
CARsgen Therapeutics 37,000-ft facility for clinical and early-stage commercial manufacturing was designed and built in just 12 months.
The CGMP facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency
Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time